Cohance to invest $10 million to expand cGMP bioconjugation capabilities in US
NJ Bio is currently executing a major new program for an existing innovator customer with multiple ADC candidates in their pipeline
NJ Bio is currently executing a major new program for an existing innovator customer with multiple ADC candidates in their pipeline
This strategic investment strengthens Cohance's integrated oligonucleotide platform
NorUDCA is the first?in?class treatment for Non?alcoholic Fatty Liver Disease (NAFLD) in India
During this quarter, the company achieved a key milestone of reaching 1,000 DCGI approvals
With this addition, the company’s total Installed MCC Capacity will rise to 30,000 MTPA
Currently focused on platform-related queries, elva.AI is the first step in ekincare’s broader roadmap
The Q-Switched Nd:YAG system is suitable for all skin types and offers versatility in treating dermal and epidermal pigmentation
The partnership aims to co-develop technologies set to revolutionize manufacturing of plasmid DNA (pDNA), a critical raw material for advanced medicines
Cenexi reports an EBITDA breakeven for the quarter
Subscribe To Our Newsletter & Stay Updated